USFDA nod to Sanofi Sarclisa in combo with bortezomib, lenalidomide, dexamethasone for newly diagnosed multiple myeloma not eligible for transpant Ruchika Sharma21 Sept 2024 2:25 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib,...
Sanofi Sarclisa accepted for USFDA priority review for transplant-ineligible newly diagnosed multiple myeloma Ruchika Sharma27 May 2024 11:30 AM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License...
Sarclisa plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone: Sanofi Ruchika Sharma11 Dec 2023 2:30 PM ISTParis: Sanofi has announced that the Phase 3 trial investigating Sarclisa (isatuximab) in combination with carfilzomib, lenalidomide and...
Sanofi multiple myeloma drug Sarclisa phase 3 trial meets primary endpoint of progression-free survival Ruchika Sharma10 Dec 2023 11:30 AM ISTParis: Sanofi has announced that the Phase 3 IMROZ trial evaluating the investigational use of Sarclisa (isatuximab) in combination with...
Novel drug shows early promise in treating multiple myeloma Dr. Kamal Kant Kohli12 Dec 2022 8:00 PM IST A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma, a form of bone marrow cancer, in a...
Sanofi gets USFDA nod for Sarclisa, Carfilzomib, Dexamethasone combo to treat multiple myeloma Ruchika Sharma3 April 2021 11:00 AM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (USFDA) has approved Sarclisa (isatuximab) in combination with carfilzomib and...
Sanofi Multiple Myeloma Drug Sarclisa Gets European Nod Ruchika Sharma5 Jun 2020 9:30 AM ISTSarclisa is a monoclonal antibody (mAb) that binds to a specific epitope on the CD38 receptor of MM cells
